Atypical antipsychotic agents and increased risk of diabetes: class action or differential action?

Bibliographys

• MOKDAD AH, FORD ES, BOWMAN BA et al.: Diabetes trends in the US 1990-1998. Diabetic Care (2000) 23:1278–1283.
   PubMed Web of Science ®Google Scholar
• WORLD HEALTH ORGANIZATION: Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO Consultation. WHO/ NCD/NCS/99.2. Geneva: WHO (1999).
   Google Scholar
• AMERICAN DIABETIC ASSOCIATION: Diabetes 2001 VitalStatistics. Alexandria, VA: ADA (2001).
   Google Scholar
• KARAVONEN M, PITKANIEMI J, TUOMILEHTO J: The onset age of Type 1 diabetes in Finnish children has become younger. The Finnish Childhood Diabetes Registry Group. Diabetes Care. (1999) 22:1066–1070.
   PubMed Web of Science ®Google Scholar
• JONSSON B: Revealing the cost of Type IIdiabetes in Europe. Daibetologia (2002) 45:S5–S12.
   PubMed Web of Science ®Google Scholar
• ZIMMET P, SHAW J, ALBERTI KG: Preventing Type 2 diabetes and the dysmetabolic syndrome in the real world: a realistic view. Diabet. Med. (2003) 20:693–702
   PubMed Web of Science ®Google Scholar
• ZIMMET P: Type 2 (non-Insulin-dependent) diabetes and epidemiological overview. Diabetologia (1982) 22:399-411. An excellent paper indicating the epidemiological data on Type 2 diabetes from different countries, which is useful for comparative study.
   Google Scholar
• ANANTH J, GUNATILAKE S, AQUINO S, BACH V, COSTA J: Are African-American patients at a higher risk for olanzapine-induced glucose intolerance? Psychopharmacology (2001) 157(3):324–325.
   PubMed Web of Science ®Google Scholar
• COLDITZ GA, WILLET WC, ROTNITZKY A, MANSON JE: Weight gain as a risk factor for clinical diabetes mellitus in women. Ann. Internal Med. (1995) 122:481–486.
   PubMed Web of Science ®Google Scholar
• HU FE, SIGAL RJ, RICH EDWARDS jw et al: Walking compared with vigorous physical activity and risk of Type 2 diabetes in women: a prospective study. JAMA (1999) 282:1433–1439.
   PubMed Web of Science ®Google Scholar
• CAREY VJ, WALTERS EE, COLDITZ GA et al.: Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women. The Nurses' Health Study. Am. J. Epidemiol. (1997) 145:614–619.
   PubMed Web of Science ®Google Scholar
• MATSON P, BYRNE CD, HALES CN, DAY NE, WAREHAM NJ: Do different dimensions of metabolic syndrome change together over time? Evidence supporting obesity as the central feature. Diabetes Care (2001) 24:1758–1763.
   PubMed Web of Science ®Google Scholar
• HOLT RI: Diagnosis, epidemiology and pathogenesis of diabetes mellitus: an update for psychiatrists. Br. J. Psychiatry (2004) 184\(Suppl. 47):555–563.
   Google Scholar
• THE EXPERT COMMITTEE ON THE DIAGNOSIS AND CLASSIFICATION OF DIABETES MELLITUS: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetic Care (2003) 26\(Suppl. 1):55–520.
   Google Scholar
• HARRIS MI: Impaired glucose tolerance in the US population. Diabetes Care (1989) 12:464–474.
   PubMed Web of Science ®Google Scholar
• MEIGS JB, MULLER DC, NATHAN DMBLAKE DR, ANDRES R: The natural history of progression from normal glucose tolerance to Type II diabetes in the Baltimore Longitudinal Study of Aging. Diabetes (2003) 52:1475–1484.
   PubMed Web of Science ®Google Scholar
• ALBERTI KG: The clinical implications of impaired glucose tolerance. Diabet. Med. (1996) 13:927–937.
   PubMed Web of Science ®Google Scholar
• HOENIG M, FERGUSON DC: Diagnostic utility of glycosylated hemoglobin concentrations in the cat. Domest. Anim. Endocrinol (1999) 16:11–17.
   PubMed Web of Science ®Google Scholar
• DEICHMANN RE, CASTELLO E, HORS WELL R, FRIDAY KE: Improvements in diabetic care as measured by HbAlc after a physician education project. Diabetic Care (1999) 22:1612–1616.
   PubMed Web of Science ®Google Scholar
• SNEHALATHA C, RAMACHANDRAN A, STTYAVANI K, VIJAY V: Limitations of glycosylated hemoglobin as an index of glucose intolerance. Diabetes Res. Clin. Pract. (2000) 47:129–133.
   PubMed Web of Science ®Google Scholar
• GILLERY P, HUE G, BORDAS-FONFREDE M et al.: Hemoglobin Alc determination and hemoglobinopathies: problems and strategies. Ann. Biol. Clin. (2000) 58:425–429
   PubMed Web of Science ®Google Scholar
• DEFRONZO RA: Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes (1988) 37:667–687.
   Google Scholar
• KAHN CR: Insulin resistance, insulin insensitivity, and insulin unresponsiveness: a necessary distinction. Metab. Clin. Exp. (1978) 27:1893–1902.
   PubMed Web of Science ®Google Scholar
• DEFRONZO RA, FERRANNINI E: Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care (1991) 14:173–194.
   Google Scholar
• MOLLER DE, FLIER JS: Insulin resistance- mechanisms, syndromes, and implications. N Engl. J. Med. (1991) 325:938–948.
   PubMed Web of Science ®Google Scholar
• REAVEN GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes (1998) 37:1595–1607.
   Google Scholar
• FORD ES, GILES WH, DIETZ WH: Prevalence of metabolic syndrome among US adults: findings from the third national health and nutrition examination survey. JAMA (2002) 287:356-359. This paper shows the prevalence of metabolic syndrome in the US population.
   Google Scholar
• MITRAKOU A. KELLEY D, MOKAN M, VENEMAN T, PANGBURN T, REILLY J: Role of reduction of suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl. J. Med. (1992) 326:22–29.
   PubMed Web of Science ®Google Scholar
• PRATLEY RE, WEYER C: The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus. Diabetologia (2001) 44:929–945.
   PubMed Web of Science ®Google Scholar
• UK PROSPECTIVE DIABETIC STUDY GROUP: UK Prospective Diabetic Study16. Overview of 6 years' therapy of Type II diabetes: a progressive disease. Diabetes(1995) 44:1249–1258.
   Google Scholar
• HOLMAN RR: Assessing the potential for alpha-glucosidase inhibitors in prediabetic states. Diabetes Res. Clin. Pract. (1998) 40(Suppl.):521–525.
   Google Scholar
• BLACK DW, FISHER R: Mortality in DSM III-R schizophrenia (1992) 7:109–116.
   PubMed Web of Science ®Google Scholar
• BROWN S: Excess mortality of schizophrenia: a meta-analysis. Br. J. Psychiatry (1997) 171:502–508.
   PubMed Web of Science ®Google Scholar
• DIXON L, WEIDEN P, DELAHANY J et al.: Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr. Bull. (2000) 26:903–912.
   PubMed Web of Science ®Google Scholar
• BRACELAND FJ, MEDUNA LJ, VAICHULIS JA: Delayed action of insulin in schizophrenia. Am. J. Psychiatry (1945) 102:108–110.
   Web of Science ®Google Scholar
• FREEMAN H: Resistance to insulin in mentally disturbed soldiers, carbohydrate metabolism to psychotic states. Arch. Neurol Psychaitr. (1946) 56:74–79.
   PubMedGoogle Scholar
• RYAN MC, COLLINS P, THAKORE JH: Impaired fasting glucose tolerance in first episode, drug naïve patients with schizophrenia. Am. J. Psychiatry (2003) 160:284–289.
   PubMed Web of Science ®Google Scholar
• MUKHERJEE S, DECINA P, BROCOLAV, SARACENI F, SCAPICCHIO PL: Diabetes mellitus in schizophrenic patients. Compr. Psychiatry (1996) 37:68–73.
   PubMed Web of Science ®Google Scholar
• HOLT RI, PEVELER RC, BYRNE CD: Schizophrenia, the metabolic syndrome and diabetes. Diabetes Med. (2004) 21:515–523.
   PubMed Web of Science ®Google Scholar
• KOOY FN: Hyperglycemia in mental disorders. Brain (1919) 42:214–289.
   Google Scholar
• RAPHAEL T, PARSONS JP: Blood sugar studies in dementia praecox and manic- depressive insanity. Arch. Neurol Psychiatr. (1921) 5:687–709.
   Google Scholar
• LORENZ WF: Sugar tolerance in dementia praecox and other mental states. Arch. Neurol Psychiatr. (1922) 8:184–196.
   Google Scholar
• BARRET TB, SERRE P: Blood analysis and sugar tolerance in mental disease./ Nerv. Ment. Dis. (1924) 59:561–570.
   Google Scholar
• HENRY GW, MANGAN E: Blood in personality disorders. Arch. Neurol Psychiatr. (1925) 13:743–749.
   Google Scholar
• KASANIN J: The blood sugar curve in mental disease. 11. The schizophrenia (dementia praecox) groups. Arch. Neurol Psychiatr. (1926) 16:414–419.
   Google Scholar
• FREEMAN H, RODNICK EH, SHAKOW D et al.: The carbohydrate tolerance of mentally disturbed soldiers. Psychosom. Med. (1944) 6:311–317.
   Google Scholar
• LAMBERTI JS, CRILLY J, MAHARAJ K, OLSON D, COSTEA 0: Prevalence of adult-onset diabetes among outpatients receiving antipsychotic drugs. Schizophr. Res. (2003) 60(Suppl.):360.
   Google Scholar
• LAMBERTI JS, CRILLY J, MAHARAJ K et al.: Prevalence of diabetes mellitus among outpatients with severe mental disorders receiving atypical antipsychotic drugs. Clin. Psychiatry (2004) 65:702–706.
   PubMed Web of Science ®Google Scholar
• MUKHERJEE S, SCHNUR DB, REDDY R: Family history of Type II diabetes in schizophrenic patients. Lancet (1989) 1(86361:495.
   PubMedGoogle Scholar
• ADAMS PF, MARANO MA: Current estimates from the national Health interview survey 1994: vital and health statistics series 10, number 193, DHS Publication (1995) PJS 96–1521. Hyattsville MD National Center for Health Statistics.
   Google Scholar
• DYNES JB: Diabetes in schizophrenia anddiabetes in nonpsychotic medical patients. Dis. Nero. Syst. (1969) 30:34–344.
   Google Scholar
• CHETA D, DUMITRESCU C, GEOGESCOU M, COCIOABA G, LICHIARDOPOL R, STAMORAN M: A study on the types of diabetes mellitus in first degree relatives of diabetic patients. Diabetes Metab. (1990) 16:11–15.
   Web of Science ®Google Scholar
• SHILOAH E, WITZ S, ABRAMOVITCH Y, COHEN 0, WEISS M, UNGER A: Effect of psychotic stress in non diabetic subjects on beta cell function and insulin sensitivity. Diabetes Care (2003) 26:1462–1467.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ L, MUNOZ R: Blood sugar levels in patients treated with chlorpromazine. Am. J. Psychiatry (1968) 125:253–255.
   PubMed Web of Science ®Google Scholar
• MCKEE HA, D'ARCY PE, WILSON PJ: Diabetes in schizophrenia: a preliminary study. J. Clin. Hosp. Pharmacy (1986) 11:297–299.
   PubMedGoogle Scholar
• LILLIKER SL: Prevalence of diabetes in manic depressive population. Compr. Psychiatry (1980) 21:270–275.
   PubMed Web of Science ®Google Scholar
• LEAN ME: Obesity: burdens of illness and strategies for prevention or management. Drugs lbelay (2000) 36:773–784.
   Web of Science ®Google Scholar
• HERRAN A, DE SANTIAGO A, SANDOYA M, FERNANDEZ MJ, DIEZ-MAURIQUE JF, VASQUEZ-BARQUERO JL: Determinants of smoking behavior in our patients with schizophrenia. Schizophr. Res. (2000) 41:373–381.
   PubMed Web of Science ®Google Scholar
• JESTE DV GLADSJO JA, LINDAMER LA: Medical comorbidity in schizophrenia. Schizophr. Bull. (1996) 22:413–430.
   PubMed Web of Science ®Google Scholar
• CHARATAN FB, BARLETT NG: The effect of chlorpromazine on glucose tolerance. J. Ment. Sci. (1955) 101:351–353.
   PubMed Web of Science ®Google Scholar
• HILES BW: Hyperglycemia and glucosuria following chlorpromazine therapy (letter). JAMA (1956) 162:1651.
   Web of Science ®Google Scholar
• MORAZEWSKI AS, DU BUOIS KP: The influence of chlorpromazine on intermediary carbohydrate metabolism. Arch. Int. Pharmacodyn. (1959) 120(2):201–221.
   PubMedGoogle Scholar
• KORENYI C, LOWENSTEIN B: Chlorpromazine induced diabetes. Dis. Ner. Syst. (1968) 29(12):827–828.
   PubMedGoogle Scholar
• AMDISEN A: Diabetes mellitus as a side effect of treatment with tricyclic neuroleptics. Acta Psychiatr. Scand. (1964) 4:411–414.
   Google Scholar
• THONNARD NEUMANN E: Phenothiazines and diabetes in hospitalized women. Am. J. Psychiatry (1968) 124:138–142.
   Google Scholar
• KESKINER A. EL-TOUMI A. BOUSQUET Psychotropic drugs, diabetes and chronic mental patient. Psychosomatics (1973) 14:176–181.
   PubMed Web of Science ®Google Scholar
• SUBRAMANIAM M, CHONG SA, PEK E: Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Canad. J. Psychiatry (2003) 48:345–347.
   PubMed Web of Science ®Google Scholar
• DOMON SE, WEBBER JC: Hyperglycemia secondary to olanzapine. J. Child Adolesc. Psychopharmacol (2002) 11:285–288.
   Web of Science ®Google Scholar
• MELKERSSON KI, DAHL ML: Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses. Psychopharmacology (2003) 170:157–166.
   PubMed Web of Science ®Google Scholar
• JIN H, MEYER JM, JESTE DV: Phenomenology and risk factors for new onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann. Clin. Psychiatry (2002) 22:11–19
   Google Scholar
• ANANTH J, VENKATESH R, BURGOYNE K, SARATH G: Atypical antipsychotic drug use and diabetes. Psychother. Psychosom. (2002) 71:244–254.
   PubMed Web of Science ®Google Scholar
• ••A review indicating that diabetesdissipated when the drug was withdrawn and reappeared when rechallenged with the same drug, indicating the definitive role of AAP drugs in producing diabetes.
   Google Scholar
• KOVAL MS, RAMES T, SCHWARKOPF SB: Diabetic ketoacidosis as a side effect of clozapine: a case report. Am. J. Psychiatry (1994) 151:1520–1521.
   PubMed Web of Science ®Google Scholar
• POPLI AP, KONICKI PE, JURJUS GJ, FULLER MA, JASKIW GE: Clozapine and associated diabetes mellitus. Clin. Psychiatry (1997) 58:108–111.
   PubMed Web of Science ®Google Scholar
• COLLI A, COCCIOLO M, FRANCOBANDIERA F, ROGANTIN F, CATTALINI N: Diabetic ketoacidosis associated with clozapine treatment. Diabetes Care (1999) 22:176–177.
   PubMed Web of Science ®Google Scholar
• PIERIDES M: Clozapine monotherapy and ketoacidosis. Br. J. Psychiatry (1997) 171:90–91.
   PubMed Web of Science ®Google Scholar
• BRUGMAN NJ, COHEN D, DE VRIES RH: Diabetes mellitus after treatment with clozapine. Ned. Tijdschr. Geneeskd. (2000) 144:437–439.
   PubMedGoogle Scholar
• VON HAYEK DV HUTTL V REISS J, SCHWEIGER ND, FUESSL HS: Hyperglycemia and ketoacidosis associated with olanzapine. Nervenarzt. (1999) 70:836–837.
   PubMedGoogle Scholar
• KOLLER EA, SCHNEIDER B, BENNETT K, DUBITSKY G: Clozapine-associated diabetes. Am. J. Med. (2001) 3:716–723.
   Web of Science ®Google Scholar
• KOLLER EA, DORAISWAMY PM: Olanzapine-associated diabetes mellitus. Pharmacotherapy (2002) 22:841–852.
   PubMed Web of Science ®Google Scholar
• KOLLER FA, CROSS JT, DORAISWAMY PM, MALOZOWSKI SN: Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy (2003) 23:735–744
   PubMed Web of Science ®Google Scholar
• KOLLER EA, WEBER J, DORAISWAMY PM, SCHNEIDER BS: A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. Clin. Psychiatry (2004) 65:857–863.
   PubMed Web of Science ®Google Scholar
• CROARKIN PE, JACOBS KM, BAIN BK: Diabetic ketoacidosis associated with risperidone treatment. Psychosomatics (2000) 41:369–370.
   PubMed Web of Science ®Google Scholar
• HAUPT DW, NEWCOMER JW: Risperidone-associated diabetic ketoacidosis [letter]. J. Psychosomatics (2001) 42:279–280.
   PubMed Web of Science ®Google Scholar
• MALLYA A, CHAWLA P, BOYER SK, DEROSEAR L: Resolution of hyperglycemia on risperidone discontinuation: a case report [letter]. Clin. Psychiatry (2002) 63:453-454. 65
   Google Scholar
• ANANTH J, JOHNSON KM, LEVANDER EM, HARRY JL: Diabetic ketoacidosis, neuroleptic malignant syndrome, and myocardial infarction in a patient taking risperidone and lithium carbonate. J. Clin. Psychiatry (2004) 65(5):724.
   PubMed Web of Science ®Google Scholar
• WIRSHING DA PIERRE JM, EYLER J,WEINBACH J, WIRSHING WC: Risperidone-associated new onset of diabetes. Biol. Psychiatry (2001) 50:148–149.
   PubMed Web of Science ®Google Scholar
• DOMON SE, CARGILLE CS: Quetiapine-associated hyperglycemia and hypertriglyceridemia. J. Am. Acad. Child Adolesc. Psychiatry (2002) 41:495–496.
   PubMed Web of Science ®Google Scholar
• SOBEL M, JAGGERS ED, FRANZ MA: New-onset diabetes associated with the initiation of quetiapine treatment. J. Clin. Psychiatry (1999) 60:556–557.
   PubMed Web of Science ®Google Scholar
• PROCYSHYN RM, PANDE S, TSE G: New- onset diabetes mellitus associated with quetiapine. Can. J. Psychiatry (2000) 45(7):668–669.
   PubMed Web of Science ®Google Scholar
• PFIZER: Data on file (2000).
   Google Scholar
• WIRSHING DA, SPELLBERG BJ, ERHART SM, MARDER SR, WIRSHING WC: Novel antipsychotics and new onset diabetes. Biol. Psychiatry (1998) 44:778–783.
   PubMed Web of Science ®Google Scholar
• AVRAM AM, PATEL V, TAYLOR HC, KIRWAN JP, KALHAN S: Euglycemic clamp study in clozapine-induced diabetic ketoacidosis. Ann. Pharmacother. (2001) 35:1381–1387.
   PubMed Web of Science ®Google Scholar
• HENDERSON D, CALGIERO E, GRAY C, NASRALLAH RA, HEYDEN DL, SCHONFELD DA: Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five year naturalistic study. Am. J. Psychiatry (2000) 157:975–981.
   PubMed Web of Science ®Google Scholar
• ••A five-year naturalistic study indicatingthat clozapine administration can produce a high level of diabetes and the number increases depending on the duration of its administration.
   Google Scholar
• HAGG S, JOELSSON IM, JORNDAL T, SPIGHT 0, OJA G, DAHLQVIST R: Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J. Clin. Psychiatry (1998) 59:294–299.
   PubMed Web of Science ®Google Scholar
• MELKERSSON KI, HULTING A-L, BRISMAR KE: Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. Clin. Psychiatry (1999) 60:783–791.
   PubMed Web of Science ®Google Scholar
• CHAE B-J, KANG B-J: The effect of clozapine on blood glucose metabolism. Hum. PsychopharmacoL Clin. Exp. (2001) 16:265–271.
   PubMed Web of Science ®Google Scholar
• SERNYAK MJ, GULANSKI B, LESLIE DL, ROSENHECK R: Undiagnosed hyperglycemia in clozapine-treated patients with schizophrenia. J. Clin. Psychiatry (2003) 64:605–608.
   PubMed Web of Science ®Google Scholar
• LUND BC, PERRY PJ, BROOKS JM, ARNDT S: Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Arch. Gen. Psychiatry (2001) 58:1772–1776.
   Google Scholar
• WANG PS, GLYNN RJ, GANZ DA, SCHNEEWEISS S, LEVIN R, AVORN J: Clozapine use and risk of diabetes mellitus. Clin. PsychopharmacoL (2002) 22:236–243.
   PubMed Web of Science ®Google Scholar
• LEONARD P, HALLEY A. BROWNE S: Prevalence of obesity, lipid and glucose abnormalities in outpatients prescribed clozapine. Irish Med. J. (2002) 95:119–120.
   PubMedGoogle Scholar
• KINON B, BASSON B, GILMORE JA, TOLLEFSON GD: Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J. Clin. Psychiatry (2001) 62:92–100.
   PubMed Web of Science ®Google Scholar
• CASEY D: Weight gain and glucose metabolism with atypical antipsychotics. 38th Annual Meeting Am. Cool. NeuropsychopharmacoL Acapulco, December (1999).
   Google Scholar
• MELKERSSON KI, HULTING AL, BRISMAR KE: Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. Clin. Psychiatry (2000) 61:742–749.
   PubMed Web of Science ®Google Scholar
• LINDENMAYER J-P, SMITH RC, SINGH k PARBER B, CHOUE J, KOTSAFTIS A: Hyperglycemia in patients with schizophrenia who are treated with olanzapine [letter]. Clin. PsychopharmacoL (2001) 21:351–353.
   PubMed Web of Science ®Google Scholar
• BISWAS PN, WILTON LV, PEARCE GL, FREEMANTLE S, SHAKIR SA: The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in England. Psychopharmacol. (2001) 15:265–271.
   Web of Science ®Google Scholar
• REINSTEIN MJ, SIROTOVSKAYA LA, JONES LE, MOHAN S, CHASANOV MA: Effect of clozapine-quetiapine combination therapy on weight and glycaemic control: preliminary findings. Clin. Drug Invest. (1999) 18:99–104.
   Web of Science ®Google Scholar
• MELKERSSON KI, HULTING AL: Insulin and leptin levels in patients with schizophrenia or related psychoses: a comparison between different antipsychotic agents. Psychopharmacology (2001) 154:205–212.
   PubMed Web of Science ®Google Scholar
• ••This study gives some insight into themechanism of the occurrence of diabetes.
   Google Scholar
• NEWCOMER JW, HAUPT DW, FUCETOLA R et al.: Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch. Gen. Psychiatry (2002) 59:337–345.
   PubMed Web of Science ®Google Scholar
• SERNYAK MJ, LESLIE L, ALARCON RD, LOSONCZY MS, ROSENHECK R: Association of diabetes mellitus with use of atypical neuroleptics in treatment of schizophrenia. Am. J. Psychiatry (2002) 159:561–566.
   PubMed Web of Science ®Google Scholar
• MEYER JM: A retrospective comparison of weight, lipid and glucose changes between risperidone and olanzapine-treated inpatients: metabolic outcome after 1 year. Clin. Psychiatry (2002) 63:425–433.
   PubMed Web of Science ®Google Scholar
• KORO CE, FEDDER DO, EITALIEN GJ, WEISS SS, MAGDER LS, KREYENBUHL S: Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. Br. Med. J. (2002) 325:243–248.
   PubMed Web of Science ®Google Scholar
• GIANFRANCESCO FD, GROGG AL, MAHMOUD RA, WANG R, NASRALLAH HA: Differential effects of risperidone, olanzapine, clozapine and conventional antipsychotics on Type 2 diabetes: findings from a large health plan database. J. Clin. Psychiatry (2002) 63:920–930.
   PubMed Web of Science ®Google Scholar
• BUSE JB, CAVAZONNI P, HOMBUCKLE K, HUTCHINS D, BRIER A, JAVONOVIC L: A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J. Clin. EpidemioL (2003) 56:164–170.
   PubMed Web of Science ®Google Scholar
• WIRSHING DA, BOYD JA, MENG LR, BALLON JS, MARDER SR, WIRSHING WC: The effects of novel antipsychotics on glucose and lipid levels. Clin. Psychiatry (2002) 63:856–865.
   PubMed Web of Science ®Google Scholar
• HEDENMALM K, HAGG S, STAHL M, MORTIMER 0, SPIGSET 0: Glucose intolerance with atypical antipsychotics. Drug Saf (2002) 25(15):1107–1116.
   PubMed Web of Science ®Google Scholar
• SOWELL MO, MUKHOPADHYAY N, CAVAZZONI P et al.: Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. J. Clin. Endocrinol Metab. (2002) 87:2918-2923. An interesting study indicating the use of clamp method to study the insulin secretion.
   Google Scholar
• BREIER A: Risk factors for diabetes mellitus during antipsychotic treatment. Int. J. Neuropsychopharmacology (2004) 1 (Suppl.):SP25.03.
   Google Scholar
• CARO JJ, WARD A, LEVINTON C, ROBINSON K: The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J. Clin. Psychiatry (2002) 63:1135–1139.
   PubMed Web of Science ®Google Scholar
• LINDENMAYER JP, CZOBOR P, VOLAVKA J et al.: Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am. J. Psychiatry (2003) 160(2):290–296.
   PubMed Web of Science ®Google Scholar
• FULLER FA, SHERMOCK KM, GROGG AL: Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine. Pharmacotherapy (2003) 23:1037–1043.
   PubMed Web of Science ®Google Scholar
• KABINOFF GS, TOALSON PA, HEALEY KM, MCGUIRE HC, HAY DP: Metabolic issues with atypical antipsychotics in primary care: dispelling the myths./ Clin. Psychiatry (2003) 5:6–14.
   Google Scholar
• KORNEGAY CJ, VASILAKIS-SCARAMOZZA C, JICK H: Incident diabetes associated with antipsychotic use in the United Kingdom general practice research database. Clin. Psychiatry (2002) 63:758–762.
   PubMed Web of Science ®Google Scholar
• CUNNIGHAM C, LAMBERT B, DALACK G et al.: Diabetes associated with antipsychotic use in Veterans with schizophrenia. Psycholidemiol. Drug Saf (2003) 12\(Suppl. 1):5154–5155.
   Google Scholar
• ALLISON DB, MENTORE JL, MOON SEONG H: Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry (1999) 156:1686–1696.
   PubMed Web of Science ®Google Scholar
• TAYLOR DM, MCASKILL R: Atypical antipsychotics and weight gain - a systematic review. Acta Psychiatr. Scand. (2000) 101:416–432.
   PubMed Web of Science ®Google Scholar
• BRUGHA TS, WING JK, SMITH BL: Physical health of long-term mentally ill in the community: is there unmet need? Br. J. Psychiatry (1989) 155:777–781.
   PubMed Web of Science ®Google Scholar
• KENDRICK T: Cardiovascular and respiratory risk factors and symptoms among general practice patients with long-term mental illness. Br. J. Psychiatry (1996) 169:733–739.
   PubMed Web of Science ®Google Scholar
• ALLISON DB, MENTORE JL, HERO M et al.: Antipsychotic induced weight gain: a comprehensive synthesis. Am. J. Psychiatry (1999) 156:1686–1696.
   PubMed Web of Science ®Google Scholar
• ••A review indicating the differential potencyof various AAP drugs.
   Google Scholar
• RYAN MC, THAKORE JH: Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci. (2002) 71:239–257.
   PubMed Web of Science ®Google Scholar
• THAKORE JH: Metabolic disturbance in first- episode schizophrenia. Br. J. Psychiatry (2004) 184\(Suppl. 47):5102–5105.
   Google Scholar
• PEDERSON SB, JONIER M, RICHELSEN B: Characteristics of regional and gender differences in glucocorticoid receptors and lipoprotein lipase activity in human adipose tissue. J. Clin. Endocrinol Metab. (1994) 78:1354–1359.
   PubMed Web of Science ®Google Scholar
• HAUPT DW, NEWCOMER JW: Hyperglycemia and antipsychotic medications. J. Clin. Psychiatry (2001) 62:15–36.
   PubMed Web of Science ®Google Scholar
• MEDUNA LJ, GERTY FJ, URSE VG: Biochemical disturbances in mental disorders. Arch. Neurol Psychiatry (1942) 47:38–52.
   Google Scholar
• HOLDEN RJ, PAUKULA IS: The link between diabetes and schizophrenia an immunological explanation. Aust. NZ. J. Psychiatry (1999) 33:286–287
   PubMed Web of Science ®Google Scholar
• NEWCOMER JW, HAUPT DW, FUCETOLA R et al.: Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch. Gen. Psychiatry (2002) 39:337–345.
   Google Scholar
• DWYER DS, LIU Y, BRADLEY RJ: Dopamine receptor antagonists modulate glucose uptake in rat pheochromocytoma cells. Neurosci. Lett. (1999) 274:151–154.
   PubMed Web of Science ®Google Scholar
• WALTERS JM, WARD GM, BARTON J et al.: The effect of norepinephrine on insulin secretion and glucose effectiveness in noninsulin dependent diabetes. Metabolism (1997) 46:1448–1453.
   PubMed Web of Science ®Google Scholar
• REAVEN GM, LITHELL H, LANDSBERG L: Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Engl. J. Med. (1996) 334:374–381.
   PubMed Web of Science ®Google Scholar
• LIN REAVEN GM: Syndrome X: 6 years later. J. Intern. Med. (1994) 236:13-22. An accurate description of syndrome X or the metabolic syndrome including increase in abdominal fat, hypertension, hypertriglyceridaemia, hypercholesterolaemia and insulin sensitivity.
   Google Scholar
• DAGAGO-JACK S, SANTIAGO JV: Pathophysiology of Type 2 diabetes and modes of action of therapeutic interventions. Arch. Intern. Med. (1997) 157:1802-1817. A good review article that deals with the various options in treating diabetes Type 2 depending on what stage the disease is in.
   Google Scholar
• YAZICI KM, ERBAS T, YAZICI AH: The effect of clozapine on glucose metabolism. Exp. Clin. Endocrinol Diabetes (1998) 106:475–477.
   PubMed Web of Science ®Google Scholar
• GHAELI P, DUFRESNE RL: Serum triglycerides in patients treated with clozapine. Am. J. Health Sys. Pharm. (1996) 53:2709–2081.
   Google Scholar
• OSSER DN, NAJARIAN DM, DUFRESNE RL: Olanzapine increases weight and serum triglyceride levels. Clin. Psychiatry (1999) 60:767–770.
   PubMed Web of Science ®Google Scholar
• GHAELI P, DUFRESNE RL: Elevated serum triglycerides on clozapine resolve with risperidone. Pharmacotherapy (1995) 15:382.
   Google Scholar
• SPIVAK B, ROITMAN S, VERED Y et al.: Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine. Clin. Neuropharmacol (1998) 21:245–250.
   PubMed Web of Science ®Google Scholar
• SPIVAK B, LAMSCHTEIN C, TALMON Yet al.: The inpact of clozapine treatment on serum lipids in chronic schizophrenic patients. Clin. Neuropharmacol (1999) 22:98–101.
   Google Scholar
• MITTELMAN SD, BERGMAN RN: Inhibition of lipolysis causes suppression of endogenous glucose production independent of changes in insulin. Am. J. Physiol. Endocrinol. Metab. (2000) 279:E630–E637.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. J. Clin. Psychiatry (2004) 65:267–272.
   PubMed Web of Science ®Google Scholar